Relebactam is a novel, non‑β‑lactam diazabicyclooctane β‑lactamase inhibitor developed by Merck. It has no intrinsic antibacterial activity but potently restores the activity of carbapenems (e.g., imipenem) against multidrug‑resistant (MDR) Gram‑negative bacteria by blocking serine β‑lactamases.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea